SS Innovations International, Inc. (NASDAQ: SSII) has achieved a significant milestone with its SSI Mantra surgical robotic system. The company announced that the SSI Mantra has received approval for telesurgeries in Indonesia and the Philippines, and it has surpassed the milestone of 150 cumulative telesurgeries successfully performed primarily in India.
The SSI Mantra has demonstrated its advanced capabilities with recent highlights including 18 inter-hospital telesurgeries performed between two Indian cities, where 13 gastric bypass procedures and 5 complex gynecological surgeries were successfully completed. Additionally, a robotic telesurgery marathon took place at SS Innovations' headquarters where nine surgeons utilized the SSI Mantra to perform 24 telesurgeries within a 12-hour period on patients located across multiple locations in India, including intricate cardiac surgeries.
Dr. Sudhir Srivastava, Chairman of the Board and CEO of SS Innovations, expressed enthusiasm about the approval for telesurgeries in Indonesia and the Philippines and the milestone of more than 150 successful telesurgeries, indicating significant traction in enabling state-of-the-art remote surgical care. He highlighted the SSI Mantra's advanced telesurgery capabilities, empowering the cross-sharing of physicians' expertise and dismantling traditional geographical barriers to care, furthering the company's mission of driving equitable access to quality healthcare.
Furthermore, SS Innovations is hosting the Global Multi-Specialty Robotic Surgery Conference 2026 (SMRSC 2026) in New Delhi, India, where distinguished surgeons, global thought leaders, and prominent innovators in robotic and minimally invasive surgery will convene. More than 20 live telesurgeries will be performed using the SSI Mantra during the conference, spanning multiple specialties and led by top experts in robotic surgery.
SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies with the vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. Their product range includes the proprietary SSI Mantra surgical robotic system and the comprehensive suite of SSI Mudra surgical instruments, supporting a variety of surgical robotic procedures, including cardiac surgery. The company, headquartered in India, aims to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. As a result of these announcements, the company's shares have moved 7.43% on the market, and are now trading at a price of $5.93. If you want to know more, read the company's complete 8-K report here.
